# PHARMacogene VARiation Consortium

> **NIH NIH R24** · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · 2020 · $174,120

## Abstract

PROJECT SUMMARY
In this administrative supplemental proposal, we outline a plan to continue the mission of the
Pharmacogene Variation (PharmVar) Consortium. PharmVar succeeded the Human Cytochrome
P450 (CYP) Allele Nomenclature Database which was founded in 2000 and served the
pharmacogenetics community for over 15 years. Over the past three years PharmVar has taken
the original web pages to a new level and built a ‘Next-Generation’ Pharmacogene Variation data
repository to inform basic and clinical research in the field of drug metabolism, disposition and
response. Information is highly curated to provide users high-quality and standardized
information. This was achieved by closely working with the PharmGKB, but also the direct
involvement of PGx community members. PharmVar has also developed a series of database
features to display complex data in useful and easy to understand ways. PharmVar has, and will
continue, to engage with and listen to PGx members to maximize the utility and value of this
resource.
Contingent on funding over the next year, PharmVar will focus on a single goal, i.e. the provision
of high-quality pharmacogene nomenclature to the PGx community. In addition to day-to day
operations, we will update information of genes in the database (i.e. review new submissions,
update functional information, etc.), complete transitions of genes currently being curated,
update source documentation and add the SLCO1B1 drug transporter gene to PharmVar for
which no formal nomenclature exists (this gene has been prioritized by the Steering Committee).
The recently developed application programming interface (beta version) will be optimized to
facilitate data transfer to the PharmGKB, other database, as well as users. PharmVar also plans
to add limited new content, which has already been compiled (e.g. allele activity scores), which
is essential information for the translation of genotype to phenotype to facilitate grouping of
samples/subjects for data analysis.
The PharmVar database has become an integral part for PGx research at large, nationally and
globally, and is viewed by many as an invaluable go-to resource.

## Key facts

- **NIH application ID:** 10202114
- **Project number:** 3R24GM123930-03S1
- **Recipient organization:** CHILDREN'S MERCY HOSP (KANSAS CITY, MO)
- **Principal Investigator:** Andrea Gaedigk
- **Activity code:** R24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $174,120
- **Award type:** 3
- **Project period:** 2017-08-01 → 2021-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10202114

## Citation

> US National Institutes of Health, RePORTER application 10202114, PHARMacogene VARiation Consortium (3R24GM123930-03S1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10202114. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*